OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SOLV$76.7558

Solventum Corp

Medical Equipment, Supplies & DistributionVerified

Solventum Corp maintains a liquidity position with a current ratio of 1.23, indicating a moderate ability to meet short-term obligations. The company's price-to-book ratio is 2.64, suggesting that the market values the company at a premium to its book value. The debt-to-equity ratio is 1.0, indicating that the company has an equal amount of debt and equity financing. In terms of profitability, Solventum Corp has a return on equity of 30.82%, which is a strong indicator of the company's ability to generate profits from shareholders' equity. The return on assets of 10.89% suggests that the company is effectively using its assets to generate earnings. These metrics are in line with the industry's preferred metrics for evaluating profitability and returns. The company's revenue is primarily concentrated in the healthcare services and equipment sector, with no significant geographic diversification mentioned in the available data. This concentration may expose the company to sector-specific risks, such as regulatory changes or shifts in healthcare demand. Solventum Corp's growth trajectory is reflected in its financial performance, with a revenue of $8.325 billion and a net income of $1.556 billion. The company's free cash flow of $1.666 billion indicates a strong ability to fund operations and invest in growth opportunities. Analysts have provided a mean price target of $84.22, suggesting a positive outlook for the company's stock. The risk assessment for Solventum Corp indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its financial flexibility. However, the low dilution risk suggests that the company is not expected to issue a significant amount of new shares in the near term. Recent events and filings do not indicate any major changes in the company's operations or financial strategy. The company's capital expenditure of -$379 million suggests that it is generating more cash from operations than it is spending on capital projects. This could be a sign of efficient capital management or a lack of investment opportunities.

30-day price · SOLV+9.42 (+14.0%)
Low$65.13High$77.50Close$76.83As of22 May, 00:00 UTC
Profile
CompanySolventum Corp
TickerSOLV.K
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Solventum Corp is a medical equipment and supplies company that generates revenue through the distribution and sale of healthcare products and services.

Classification. Solventum Corp is classified under the Healthcare Services & Equipment business sector within the Healthcare economic sector, with a classification confidence of 0.92.

Solventum Corp maintains a liquidity position with a current ratio of 1.23, indicating a moderate ability to meet short-term obligations. The company's price-to-book ratio is 2.64, suggesting that the market values the company at a premium to its book value. The debt-to-equity ratio is 1.0, indicating that the company has an equal amount of debt and equity financing. In terms of profitability, Solventum Corp has a return on equity of 30.82%, which is a strong indicator of the company's ability to generate profits from shareholders' equity. The return on assets of 10.89% suggests that the company is effectively using its assets to generate earnings. These metrics are in line with the industry's preferred metrics for evaluating profitability and returns. The company's revenue is primarily concentrated in the healthcare services and equipment sector, with no significant geographic diversification mentioned in the available data. This concentration may expose the company to sector-specific risks, such as regulatory changes or shifts in healthcare demand. Solventum Corp's growth trajectory is reflected in its financial performance, with a revenue of $8.325 billion and a net income of $1.556 billion. The company's free cash flow of $1.666 billion indicates a strong ability to fund operations and invest in growth opportunities. Analysts have provided a mean price target of $84.22, suggesting a positive outlook for the company's stock. The risk assessment for Solventum Corp indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could affect its financial flexibility. However, the low dilution risk suggests that the company is not expected to issue a significant amount of new shares in the near term. Recent events and filings do not indicate any major changes in the company's operations or financial strategy. The company's capital expenditure of -$379 million suggests that it is generating more cash from operations than it is spending on capital projects. This could be a sign of efficient capital management or a lack of investment opportunities.
Key takeaways
  • Solventum Corp has a strong return on equity of 30.82%, indicating effective use of shareholders' equity.
  • The company's liquidity position is moderate, with a current ratio of 1.23.
  • The company's debt-to-equity ratio is balanced at 1.0, suggesting a mix of debt and equity financing.
  • Analysts have a positive outlook, with a mean price target of $84.22.
  • The company's free cash flow of $1.666 billion provides financial flexibility for growth and operations.
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "The company's gross profit margin is expected to remain stable due to consistent demand for medical equipment and supplies.",
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$8.32B
Gross profit$4.46B
Operating income$2.10B
Net income$1.56B
R&D
SG&A
D&A
SBC
Operating cash flow$369.0M
CapEx-$379.0M
Free cash flow$1.67B
Total assets$14.29B
Total liabilities$9.24B
Total equity$5.05B
Cash & equivalents$878.0M
Long-term debt$5.04B
Valuation
Market price$76.75
Market cap$13.31B
Enterprise value$17.47B
P/E8.6
Reported non-GAAP P/E
EV/Revenue2.1
EV/Op income8.3
EV/OCF47.3
P/B2.6
P/Tangible book2.6
Tangible book$5.05B
Net cash-$4.16B
Current ratio1.2
Debt/Equity1.0
ROA10.9%
ROE30.8%
Cash conversion24.0%
CapEx/Revenue-4.5%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricSOLVActivity
Op margin25.2%3.9% medp25 -31.3% · p75 14.4%top quartile
Net margin18.7%2.4% medp25 -30.5% · p75 11.1%top quartile
Gross margin53.6%46.7% medp25 28.2% · p75 63.1%above median
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-4.5%-4.8% medp25 -11.6% · p75 -2.4%above median
Debt / equity100.0%17.9% medp25 2.7% · p75 52.2%top quartile
Observations
IR observations
Mean price target84.22 USD
Median price target84.50 USD
High price target105.00 USD
Low price target60.00 USD
Mean recommendation2.53 (1=strong buy, 5=strong sell)
Strong-buy count3.00
Buy count3.00
Hold count7.00
Sell count2.00
Strong-sell count0.00
Mean EPS estimate6.44 USD
Last actual EPS6.11 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-24 18:35 UTC#f1c98ee0
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 12:40 UTCJob: 001b820b